Kenalog Shortage: What Providers and Prescribers Need to Know in 2026

Triamcinolone acetonide injectable suspension (Kenalog) is one of the most widely used corticosteroids in ambulatory care — relied upon by rheumatologists, orthopedic surgeons, dermatologists, allergists, primary care providers, and pain management specialists. The ongoing 2026 shortage is creating real clinical disruption. This guide is written for prescribers and clinical staff managing patients who depend on Kenalog.

Current Shortage Status (ASHP, 2025–2026)

The American Society of Health-System Pharmacists (ASHP) Drug Shortage Database confirms an active shortage of triamcinolone acetonide injectable suspension across multiple manufacturers. Key facts:

Eugia US: Discontinued 40 mg/mL 5 mL and 10 mL vials mid-2025. Permanent exit from this market.

Hikma: 40 mg/mL 1 mL vials on allocation to contracted customers only.

Long Grove: 5 mL and 10 mL vials on intermittent back order due to increased demand.

Viatris: 5 mL and 10 mL vials on back order; estimated release late-June 2026.

Teva: Shortage; reason not disclosed.

Amneal: Allocation to contracted customers only.

Bristol-Myers Squibb (Kenalog brand): Some presentations available; reason for shortage not disclosed.

Clinical Considerations During the Shortage

During a multi-manufacturer shortage, providers should consider the following approaches to manage their triamcinolone acetonide supply strategically:

Prioritize allocation: Reserve remaining stock for patients with the most acute need (active gout flares, severe arthritis exacerbations, significant skin lesions) while transitioning stable patients to alternatives.

Vial sharing: For multi-dose vials (5 mL or 10 mL), coordinate clinic scheduling to use opened vials efficiently within their sterility window (per USP <797> guidelines).

Contact your GPO: Group purchasing organization members may have access to allocated supply unavailable to independent pharmacies.

Therapeutic Alternatives and Dosing Equivalencies

The following alternatives are appropriate substitutes for most triamcinolone acetonide indications. Dosing conversions are approximate — always use clinical judgment and consider individual patient factors:

Methylprednisolone acetate (Depo-Medrol): Best overall substitute for both IM and intra-articular use. Anti-inflammatory equivalency: methylprednisolone 4 mg ≈ triamcinolone 4 mg. Typical intra-articular doses: 20–80 mg depending on joint size. Does not contain benzyl alcohol.

Betamethasone acetate/sodium phosphate (Celestone Soluspan): Long-acting; useful for joint and soft tissue injections. Typical dose: 0.5–9 mg depending on indication. More soluble than triamcinolone; slightly different particle characteristics.

Triamcinolone hexacetonide (Aristospan): Direct triamcinolone alternative with longer intra-articular duration. Check availability — also on shortage in some markets.

Dexamethasone sodium phosphate: Non-particulate; appropriate for indications where particulate steroids are contraindicated. Shorter duration of action (~2–4 weeks). Conversion: dexamethasone 0.75 mg ≈ triamcinolone 4 mg.

Special Considerations by Indication

Intra-articular injections (OA, RA, gout): Depo-Medrol 20–80 mg or Celestone 0.5–9 mg; clinical evidence suggests comparable efficacy to triamcinolone acetonide for most joint conditions.

Intralesional (dermatology): Kenalog-10 is preferred for intralesional use; if unavailable, diluted Depo-Medrol (2.5–10 mg/mL) is an accepted alternative for keloids, alopecia areata, and inflammatory plaques.

Systemic IM (allergic conditions, MS flares): For MS flares, consider IV methylprednisolone (Solu-Medrol 500–1000 mg/day × 3–5 days) as first-line. For systemic allergy management, IM methylprednisolone 40–80 mg is an appropriate substitute.

Compounding as a Short-Term Option

When commercial triamcinolone acetonide is unavailable, compounded triamcinolone acetonide may be used under FDA shortage provisions. Facilities must comply with USP <797> sterile compounding standards. 503B outsourcing facilities are preferred for large practice volumes, as they operate under FDA oversight and do not require patient-specific prescriptions. Verify your compounding pharmacy's accreditation (PCAB) before use.

Patient Communication Tips During the Shortage

Proactively notify patients whose next injection appointment may be affected before they arrive

Reassure patients that therapeutically equivalent alternatives exist and explain the switching rationale

Direct patients who are independently searching for their prescription to medfinder.com/providers

For more guidance on helping your patients navigate the shortage, visit medfinder for providers or read our clinical companion: How to Help Your Patients Find Kenalog In Stock.